Clinical Trial Update: Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating jaktinib for severe COVID-19 pneumonia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia

Drugs mentioned

• Jaktinib (jaktinib)

Snippet

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Conditions: COVID-19, Pneumonia | Phase 2 | Status: WITHDRAWN